RBC Capital Lowers Exelixis (EXEL) Price Target to $43

Exelixis, Inc. (NASDAQ:EXEL) is one of the 15 Set-It-and-Forget-It Stocks to Buy in 2026. RBC Capital Lowers Exelixis (EXEL) Price Target to $43 On March 2, 2026, Exelixis, Inc. (NASDAQ:EXEL) saw its price target from RBC Capital lowered from $46 to $43. The firm’s Sector Perform rating was maintained on the stock. In a research note, RBC Capital pointed out that after the reporting of the data from the HIF-2alpha inhibitors study by Exelixis, Inc. (NASDAQ:EXEL)’s competitor Merck (MRK), the share value ...